Breast Cancer | Physician's Weekly
Advertisement

Breast Cancer

Evolution of low HER2 expression between early and advanced-stage breast cancer.

Jan 17, 2022

Low human epidermal growth factor receptor 2 (HER2) expression is emerging as an actionable biomarker for the treatment of breast cancer (BC) with novel anti-HER2 drugs. However, the evolution of this...

Signaling pathways modulated by miRNAs in breast cancer angiogenesis and new therapeutics.

Jan 17, 2022

MicroRNAs (miRNAs) act as oncogenes or tumor suppressors by suppressing the expression of target genes, some of which are engaged in angiogenic signaling pathways directly or indirectly. Tumor develop...

Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study.

Jan 10, 2022

Research on the role of insulin resistance (IR) in breast cancer risk in premenopausal women is scarce. We aimed to investigate the relationship between IR and the development of breast cancer in prem...

Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A-PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1.

Jan 03, 2022

SIN3A, a scaffold protein has regulatory functions in tumor biology. Through its Paired amphipathic helix (PAH2) domain, SIN3A interacts with PHF12 (PF1), a protein with SIN3 interaction domain (SID) ...

Effect of postmastectomy radiotherapy on pTN breast cancer patients with different molecular subtypes.

Dec 27, 2021

To clarify the effect of postmastectomy radiotherapy (PMRT) on pTN breast cancer patients with different molecular subtypes.We retrospectively analyzed the data of 5442 patients with pTN breast cancer...

The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer.

Dec 27, 2021

The expression of major histocompatibility complex class I (MHC I) has previously been reported to be negatively associated with estrogen receptor (ER) expression. Furthermore, MHC I expression, level...

Subgroup analyses demonstrate consistent OS benefit of ribociclib in patients with locally advanced/metastatic HR-positive/HER2-negative breast cancer

Dec 15, 2021

In three MONALEESA phase 3 trials, addition of ribociclib to adjuvant endocrine therapy improved overall survival (OS) in post-menopausal patients with locally advanced/metastatic HR-positive/HER2-neg...

Elacestrant may improve outcomes for patients whose metastatic breast cancer progressed on prior endocrine therapy

Dec 15, 2021

According to the first results of the EMERALD trial, elacestrant, the first oral selective estrogen receptor degrader, shows clinical benefit over standard endocrine therapy in patients with ER-positi...

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab robustly benefits EFS in patients with early triple-negative breast cancer

Dec 15, 2021

Primary analysis of the KEYNOTE-522 trial shows a statistically significant and clinically meaningful improvement in the event-free survival (EFS) of neoadjuvant pembrolizumab plus chemotherapy follow...

Single-cell spatial analysis may help predict response to neoadjuvant immunotherapy in triple-negative breast cancer

Dec 15, 2021

A next-generation technology allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME). In the NeoTRIPaPDL1 trial, it provid...

Addition of adjuvant palbociclib to standard endocrine therapy does not improve outcomes in patients with early HR-positive breast cancer

Dec 15, 2021

Although adjuvant therapy with CDK4/6 inhibitors has shown to benefit patients with advanced/metastatic HR-positive/HER2-negative breast cancer, the final analysis of the PALLAS trial shows no benefit...

Using genomics to match treatments improves outcomes for certain patients with metastatic breast cancer

Dec 15, 2021

The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/II tiers of...

Loss of ASXL1 tumor suppressor promotes resistance to CDK4/6 inhibitors.

Dec 15, 2021

The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called ‘accelerated mutagenesis’, researchers unraveled the role of ASXL1 loss. Initial findings in ER-posi...

Black women are more likely to develop lymphedema following breast cancer treatment

Dec 15, 2021

Development of breast cancer-related lymphedema is not equally distributed between races. Black women experienced higher rates of breast cancer-related lymphedema than White women, results of a prospe...

Promising anti-tumour activity of the CDK7-inhibitor samuraciclib (plus fulvestrant) in pre-treated ER-positive/HER2-negative metastatic breast cancer

Dec 15, 2021

Efficacy of second-line treatment option for patients with ER-positive/HER2-negative metastatic breast cancer who progress on an aromatase inhibitor plus CDK4/6 inhibitor is poor. In a first-in-human ...

ctDNA is prognostic and predictive for response to ribociclib/letrozole

Dec 15, 2021

The phase 3 BioItaLEE trial demonstrates that pre-treatment circulating tumor DNA (ctDNA) and early dynamics of ctDNA represent promising prognostic and predictive biomarkers in patients with HR-posit...

Olaparib is well tolerated as an additional adjuvant treatment

Dec 15, 2021

Adjuvant treatment with the PARP inhibitor olaparib showed beneficial effects for patients with BRCA1/2 mutations and high-risk, HER2-negative, early-stage, primary breast cancer. In addition, patient...

Neratinib/trastuzumab is clinically active in patients with heavily pre-treated, metastatic, HER2-mutated breast cancer.

Dec 15, 2021

Both patients with heavily pre-treated HR-positive/HER2-negative, HER2-mutated, metastatic breast cancer and patients with heavily pre-treated HER2-mutated metastatic triple-negative breast cancer (TN...

Aromatase inhibitors outperform tamoxifen in reducing recurrence in pre-menopausal women

Dec 15, 2021

In pre-menopausal women with early-stage, ER-positive breast cancer, adjuvant ovarian suppression can be combined with tamoxifen or an aromatase inhibitor. A meta-analysis of 4 randomized controlled t...

Taxane with or without anthracycline?

Dec 15, 2021

Taxane with or without anthracycline reduces the recurrence rate of early-stage breast cancer. A meta-analysis based on data of 18,203 participants now demonstrates anthracycline/taxane to reduce the ...